Status
Completed
Phase
Phase 2
Enrollment
40
Locations
0
Results
Not posted
Publications
0
Study summary
The present study aims to look at the effect of terlipressin infusion on blood loss and blood transfusion needs during Whipple procedure
Interventions
DRUG
Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
DRUG
Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Timeline
First posted
Jun 28, 2018
Study start
May 2016
Primary completion
Jul 2017
Study completion
Jul 2017
Results posted
Not reported
Registry updated
May 22, 2023
Outcomes
Intraoperative blood loss
Time frame · intaoperative periods
Amount of intraoperative blood loss in ml
Patients needing blood transfusion
Time frame · intaoperative periods
Number of patients needing blood transfusion
Red blood cell units transfused
Time frame · intaoperative periods
The number of red blood cell units transfused
portal pressure changes
Time frame · intaoperative periods
portal pressure changes in mmHg
ICU stay
Time frame · postoperative periods
ICU stay in days
Eligibility
Inclusion Criteria: * All patients older than 18 years of age, * ASA classification class I and II, * Patients assigned for Whipple procedure. Exclusion Criteria: * Preoperative renal failure, * Severe liver dysfunction (Child-Turcotte-Pugh grade C), * Hyponatremia (Na+ \<132mmol/l), * Severe valvular heart disease, * Heart failure, * Symptomatic coronary heart disease, * Bradycardic arrhythmia (heart rate \< 60/min), * Peripheral artery occlusive disease (clinical stadium II-IV), * Uncontrolled arterial hypertension (Blood pressure \>160/100mmHg despite intensive treatment), * Pregnancy.
Study locations
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.